Connect with us

Eyecare

Allergan Sued Over Dry Eye Drug Marketing Tactics

mm

Published

on

It’s accused of trying to block out competition.

Shire Plc has filed a lawsuit accusing Allergan Plc of antitrust violations in connection with Allergan’s dry eye medication Restasis, Reuters reports.

The lawsuit claims that Allergan’s goal was to maintain Restasis’ position in Medicare prescription drug plans. Allergan sought to prevent the Shire drug Xiidra from getting a foothold in that market, according to the suit.

Shire claims that Allergan used “bundled discounts, exclusive dealing, coercion and interference to unlawfully ‘block’ Shire from competing with it.”

Allergan wants to “maintain its monopoly in the Part D market at all costs,” according to Shire.

Advertisement

An Allergan spokesman told Reuters the lawsuit was without merit.

The suit was filed in U.S. District Court in New Jersey.

Read more at Reuters

SPONSORED VIDEO

SPONSORED BY VARILUX

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular